1. Short title This Act may be cited as the Bring Entrepreneurial Advancements To Consumers Here In North America Act . 2. Findings Congress finds as follows: (1) On December 31, 2019, China reported a cluster of cases of pneumonia in Wuhan, Hubei Province. (2) On January 7, 2020, Chinese authorities identified the virus as a novel coronavirus which would later be understood to cause a respiratory illness in humans, known as COVID-19. (3) The spread of the coronavirus and the geographic location of the original outbreak caused reverberations in medical supply chains that reached around the world. (4) The Coronavirus pandemic highlights the United States dependency on China for critical medical supplies and pharmaceuticals. (5) China is the largest exporter of medical devices to the United States. (6) China is the second largest exporter of drugs and biologics, or drugs from natural sources, to the United States. (7) Chinese pharmaceutical companies produce more than 90 percent of our supply of antibiotics, vitamin C, ibuprofen, and hydrocortisone. (8) China is a communist regime and geopolitical adversary. China should not control the United States pharmaceutical and medical device supply chains. (9) A recent article in the state-controlled news agency, Xinhua stated, “If China retaliates against the United States at this time … it will also announce strategic control over medical products and ban exports to the United States. Then the United States will be caught in the ocean of the new coronaviruses.”. (10) Companies should be incentivized through a competitive tax structure to manufacture and produce pharmaceuticals and medical devices in the United States. 3. Tax incentives for relocating manufacturing of pharmaceuticals and medical supplies and devices to the United States (a) Accelerated depreciation for nonresidential real property Section 168 of the Internal Revenue Code of 1986 is amended by adding at the end the following new subsection: (n) Accelerated depreciation for nonresidential real property